{"prompt": "['As a minimum requirement, the initial notification should provide the following', 'information:', 'Study number', 'Patient number', 'Gender', 'Date of birth', 'Name of investigator and full study site address', 'Details of SAE', 'Criterion for classification as \"serious\"', 'Study drug code, or name if unblinded, and treatment start date and stop date, if', 'applicable', 'Date of SAE onset', 'Causality assessment (if sufficient information is available to make this classification)', 'The sponsor will request clarification of omitted or discrepant information from the initial', 'notification. The investigator or an authorized delegate is responsible for providing the', \"requested information to the sponsor within 24 hours of the sponsor's request.\", 'Initial reports of SAEs must be followed later with detailed descriptions, including clear', 'photocopies of other documents as necessary (e.g., hospital reports, consultant reports,', \"autopsy reports), with the study patient's personal identifiers removed. All relevant\", 'information obtained by the investigator through review of these documents will be', 'recorded and provided to the sponsor within 24 hours of receipt of the information. If a', 'new SAE Report Form is provided, then the investigator must sign and date the form.', 'The sponsor may also request additional information on the SAE, which the investigator', 'or an authorized delegate must provide to the sponsor within 24 hours of the request.', 'The SAE reporting contact information will be provided to all participating study sites by', 'the contract research organization (CRO) on behalf of the sponsor before study', 'initiation.', 'Intra-Cellular Therapies, Inc. Confidential', '51 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['9.4.3 Reporting of SAEs and AEs to FDA and Other Regulatory Authorities', 'The sponsor or designee will be responsible for complying with mandatory reporting of', 'safety events to the Food and Drug Administration (FDA) and other regulatory', 'authorities.', '9.4.4', 'Reporting of Pregnancy', 'Pregnancy is not regarded as an AE unless there is a suspicion that an investigational', 'product may have interfered with the effectiveness of a contraceptive medication. Any', 'pregnancy that occurs in a patient or a partner of a patient during study participation', 'must be reported using a clinical study pregnancy form. To ensure patient safety, each', 'pregnancy must be reported to the sponsor within 2 weeks of learning of its occurrence.', 'The pregnancy must be followed up to determine outcome (including spontaneous', 'miscarriage, elective termination, normal birth, or congenital abnormality) and status of', 'mother and child. Pregnancy will result in immediate discontinuation from the study.', 'Pregnancy complications and elective terminations for medical reasons should not be', 'reported as an AE or SAE. Spontaneous miscarriages must be reported as an SAE.', \"Any SAE occurring in association with a pregnancy, brought to the investigator's\", 'attention after the patient has completed the study, and considered by the investigator', 'as possibly related to the study treatment, must be promptly reported to ITI according to', 'Section 9.4.2.', '9.5', 'Halting Rules', 'Individual patient participation in the study may be stopped at any time at the discretion', 'of the investigator. Individual patient participation may also be stopped at any time at', 'the request of the sponsor. Additionally, the sponsor may place a temporary or', 'permanent suspension of enrollment at any site or for the entire study. Reasons for', 'stopping or suspending patient participation and/or enrollment include, but are not', 'limited to, violation of Inclusion/exclusion criteria, major protocol deviation(s), or safety', 'concern.', 'Review of serious, unexpected, and related AEs by the IRB/IEC, the sponsor, or the', 'FDA or relevant local regulatory authorities may also result in suspension of further trial', 'interventions/administration of study product at a site. The FDA or other local regulatory', 'authorities and study sponsor retain the authority to suspend additional enrollment and', 'study interventions/administration of study product for a site or the entire study, as', 'applicable.', 'Although ITI has every intention of completing the study, ITI reserves the right to', 'discontinue the study at any time for clinical or administrative reasons.', 'Intra-Cellular Therapies, Inc. Confidential', '52 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']['10 STUDY OVERSIGHT', '10.1', 'External Data Monitoring Committee', \"In addition to the investigator's responsibility for oversight, study oversight will be under\", 'the direction of the sponsor and the Medical Monitor(s). The Medical Monitor(s) will be', 'available in real time to review and recommend appropriate action regarding adverse', 'events and other safety issues. Blinded safety data across sites will be monitored', 'throughout the study. Blinded data regarding enrollment and retention, adverse events,', 'outlier safety parameters (e.g. clinical laboratory results, ECG parameters) and other', 'relevant parameters will be reviewed regularly. If necessary, additional steps may be', 'taken to ensure data integrity and protocol compliance.', 'Intra-Cellular Therapies, Inc. Confidential', '53 ITI-007-404 Protocol Amendment V 1.3 November 5, 2018']\n\n###\n\n", "completion": "END"}